Dr Dubri Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 22-06-2024
- Paid Up Capital ₹ 0.10 M
as on 22-06-2024
- Company Age 21 Year, 3 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 2.30 M
as on 22-06-2024
- Revenue -13.60%
(FY 2020)
- Profit 50.76%
(FY 2020)
- Ebitda 8.90%
(FY 2020)
- Net Worth 8.51%
(FY 2020)
- Total Assets 25.24%
(FY 2020)
About Dr Dubri Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.30 M.
Himanshu Anand and Sudhanshu Anand serve as directors at the Company.
- CIN/LLPIN
U24231DL2003PTC122182
- Company No.
122182
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Sep 2003
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dr Dubri Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Himanshu Anand  | Director | 25-Aug-2018 | Current |
| Sudhanshu Anand | Director | 10-Sep-2003 | Current |
Financial Performance of Dr Dubri Pharmaceuticals.
Dr Dubri Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 13.6% decrease. The company also saw a substantial improvement in profitability, with a 50.76% increase in profit. The company's net worth moved up by a moderate rise of 8.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr Dubri Pharmaceuticals?
In 2018, Dr Dubri Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
D P Gupta Associates Private LimitedActive 11 years 9 monthsHimanshu Anand and Sudhanshu Anand are mutual person
- Drm Global Healthcare Private LimitedActive 6 years 8 months
Himanshu Anand and Sudhanshu Anand are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Punjab & Sindh Bank Creation Date: 06 Jul 2009 | ₹2.30 M | Open |
How Many Employees Work at Dr Dubri Pharmaceuticals?
Dr Dubri Pharmaceuticals has a workforce of 5 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr Dubri Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr Dubri Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
